Login to Your Account

Medivir Puts $90M Bid on the Table for BioPhausia

By Cormac Sheridan

Wednesday, April 13, 2011
Although it does not expect to launch its hotly anticipated hepatitis C drug TMC435 until late 2013, at the earliest, Medivir AB is putting in place the supporting infrastructure now, by bidding to acquire specialty pharma firm BioPhausia AB, in a cash-and-shares deal valued at SEK565 million (US$90.1 million).

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription